Moreover, it has been proven that patients with nonsquamous STK11-mutant NSCLC are less likely than STK11 wild-type patients to respond to durvalumab monotherapy or durvalumab in combination with tremelimumab therapy (anti-CTLA-4 mAb), and their tumors show increased expression of genes and cytokines that activate STAT3 signaling pathway [54]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.